Medigene is a global leader in T Cell immunology.
Growing clinical pipeline in multiple indications and strong collaborations.
A high-throughput platform for antigen and TCR discovery.
Listed on the Frankfurt Stock Exchange (Deutsche Börse) with a market cap of EUR330 million.
Fundraising to expand the company's ongoing clinical program with its T-cell receptor-modified T cells (TCR-T) and to progress its pipeline of potential TCR-T candidates for future clinical development.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acted as Lead Manager alongside Guggenheim Securities and Baader Bank.
EUR32.3 million raised in an oversubscribed Accelerated Bookbuild targeting institutional investors in Europe and in the US.
Offering priced at EUR 14.5 per share representing a discount of 2.3% to the last market closing price.
Strong demand enabled QVT Financial LP, a major shareholder of Medigene, to sell c. 1.1 million shares in a secondary offering as part of a general restructuring across its funds.